IL213116B - Combinations against tumors that include antibodies that selectively contain 38cd and malaflan - Google Patents

Combinations against tumors that include antibodies that selectively contain 38cd and malaflan

Info

Publication number
IL213116B
IL213116B IL213116A IL21311611A IL213116B IL 213116 B IL213116 B IL 213116B IL 213116 A IL213116 A IL 213116A IL 21311611 A IL21311611 A IL 21311611A IL 213116 B IL213116 B IL 213116B
Authority
IL
Israel
Prior art keywords
melphalan
containing antibodies
antibodies recognizing
combinations containing
recognizing specifically
Prior art date
Application number
IL213116A
Other languages
English (en)
Hebrew (he)
Other versions
IL213116A0 (en
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40578382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL213116(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IL213116A0 publication Critical patent/IL213116A0/en
Publication of IL213116B publication Critical patent/IL213116B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL213116A 2008-11-28 2011-05-24 Combinations against tumors that include antibodies that selectively contain 38cd and malaflan IL213116B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08291116A EP2191840A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
PCT/IB2009/055389 WO2010061357A1 (en) 2008-11-28 2009-11-27 Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan

Publications (2)

Publication Number Publication Date
IL213116A0 IL213116A0 (en) 2011-07-31
IL213116B true IL213116B (en) 2018-11-29

Family

ID=40578382

Family Applications (1)

Application Number Title Priority Date Filing Date
IL213116A IL213116B (en) 2008-11-28 2011-05-24 Combinations against tumors that include antibodies that selectively contain 38cd and malaflan

Country Status (32)

Country Link
US (1) US9259406B2 (OSRAM)
EP (2) EP2191840A1 (OSRAM)
JP (3) JP2012510461A (OSRAM)
KR (1) KR101733252B1 (OSRAM)
CN (1) CN102264385B (OSRAM)
AR (1) AR074219A1 (OSRAM)
AU (1) AU2009321249B2 (OSRAM)
BR (1) BRPI0921864B1 (OSRAM)
CA (1) CA2744990C (OSRAM)
CL (1) CL2011001254A1 (OSRAM)
CO (1) CO6440557A2 (OSRAM)
CR (1) CR20110280A (OSRAM)
EA (1) EA026867B1 (OSRAM)
EC (1) ECSP11011062A (OSRAM)
HN (1) HN2011001417A (OSRAM)
IL (1) IL213116B (OSRAM)
MA (1) MA32896B1 (OSRAM)
ME (1) ME01136B (OSRAM)
MX (1) MX342625B (OSRAM)
MY (1) MY164577A (OSRAM)
NI (1) NI201100105A (OSRAM)
NZ (1) NZ593027A (OSRAM)
PA (1) PA8850101A1 (OSRAM)
PE (1) PE20120340A1 (OSRAM)
SG (1) SG171820A1 (OSRAM)
SV (1) SV2011003924A (OSRAM)
TN (1) TN2011000232A1 (OSRAM)
TW (1) TWI454260B (OSRAM)
UA (1) UA107069C2 (OSRAM)
UY (1) UY32263A (OSRAM)
WO (1) WO2010061357A1 (OSRAM)
ZA (1) ZA201103925B (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0816777B2 (ja) 1988-10-13 1996-02-21 富士写真フイルム株式会社 画像形成方法
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
WO2011130624A2 (en) 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR101912957B1 (ko) * 2010-09-27 2018-10-29 모르포시스 아게 다발성 골수종 및 nhl 치료를 위한 항-cd38 항체 및 레날리도마이드 또는 보르테조밉
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
SG11201502163QA (en) 2012-09-25 2015-04-29 Morphosys Ag Combinations and uses thereof
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3063173B1 (en) 2013-10-31 2020-07-29 Sanofi Specific anti-cd38 antibodies for treating human cancers
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
PH12017500442B1 (en) 2014-09-09 2023-05-24 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
CN108136218B (zh) 2015-05-20 2022-12-13 詹森生物科技公司 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
PE20181323A1 (es) 2015-06-22 2018-08-14 Janssen Biotech Inc Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
HUE053366T2 (hu) 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US11613586B2 (en) 2016-07-15 2023-03-28 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
US20210145778A1 (en) * 2018-01-01 2021-05-20 Orbicular Pharmaceutical Technologies Pvt. Ltd. Stable Liquid Compositions of Melphalan
WO2019140410A1 (en) 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
CA3113472A1 (en) 2018-09-28 2020-04-02 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
MX2021011181A (es) 2019-03-15 2022-01-19 Morphosys Ag Anticuerpos anti-cd38 y sus composiciones farmacéuticas para el tratamiento de la enfermedad autoinmune mediada por autoanticuerpos.
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
AU2020397170A1 (en) 2019-12-05 2022-07-21 Sanofi-Aventis U.S. Llc Formulations of anti-CD38 antibodies for subcutaneous administration
KR20230142834A (ko) 2021-01-14 2023-10-11 모르포시스 아게 항-cd38 항체 및 이의 용도
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3032585A (en) 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2329940A1 (en) * 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
GB0221574D0 (en) 2002-09-17 2002-10-23 Isis Innovation Treatments
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
NZ586780A (en) * 2005-03-23 2012-02-24 Genmab As Antibodies against CD38 for treatment of multiple myeloma
EP3753576A1 (en) 2006-09-26 2020-12-23 Genmab A/S Combination treatment of cd38-expressing tumors
US20080092384A1 (en) * 2006-10-16 2008-04-24 Schaake Mark D Installation of Middle Bearing for a Crankshaft
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan

Also Published As

Publication number Publication date
UY32263A (es) 2010-06-30
AU2009321249B2 (en) 2016-06-09
TWI454260B (zh) 2014-10-01
IL213116A0 (en) 2011-07-31
EP2370094A1 (en) 2011-10-05
NI201100105A (es) 2011-12-13
US9259406B2 (en) 2016-02-16
CN102264385B (zh) 2015-05-20
CO6440557A2 (es) 2012-05-15
EA026867B1 (ru) 2017-05-31
ECSP11011062A (es) 2011-07-29
CA2744990C (en) 2019-05-07
CN102264385A (zh) 2011-11-30
EA201100864A1 (ru) 2011-12-30
KR20110096550A (ko) 2011-08-30
JP6148696B2 (ja) 2017-06-14
NZ593027A (en) 2012-12-21
PA8850101A1 (es) 2010-07-27
HK1164165A1 (en) 2012-09-21
CL2011001254A1 (es) 2012-01-27
CR20110280A (es) 2011-09-20
AU2009321249A1 (en) 2010-06-03
CA2744990A1 (en) 2010-06-03
KR101733252B1 (ko) 2017-05-08
ME01136B (me) 2013-03-20
JP2015205890A (ja) 2015-11-19
UA107069C2 (uk) 2014-11-25
BRPI0921864B1 (pt) 2022-11-16
US20110274686A1 (en) 2011-11-10
WO2010061357A1 (en) 2010-06-03
HN2011001417A (es) 2014-01-13
BRPI0921864A2 (pt) 2018-10-09
TW201023855A (en) 2010-07-01
SG171820A1 (en) 2011-07-28
ZA201103925B (en) 2012-09-26
AR074219A1 (es) 2010-12-29
MA32896B1 (fr) 2011-12-01
JP2012510461A (ja) 2012-05-10
MY164577A (en) 2018-01-15
EP2191840A1 (en) 2010-06-02
JP2017141233A (ja) 2017-08-17
PE20120340A1 (es) 2012-04-17
MX2011005670A (es) 2011-09-30
SV2011003924A (es) 2011-10-07
MX342625B (es) 2016-10-06
TN2011000232A1 (en) 2012-12-17

Similar Documents

Publication Publication Date Title
IL213116A0 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
IL213115A0 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine
ZA201103920B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide
ZA201103923B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine
ZA201304845B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
GB2462709B (en) Compound gesture recognition
ZA201102119B (en) Improved antibody libraies
EP2241578A4 (en) ANTI-CLDN6 ANTIBODIES
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
IL216731A (en) And antibodies against p95 – her2 and their uses
GB0821100D0 (en) Antibodies
PL2285237T3 (pl) Napój instant na bazie zbóż
IL207581A0 (en) Anti-tyrp1 antibodies
IL209129A0 (en) Anti-pirb antibodies
GB2477044B (en) Compound gesture recognition
GB0818356D0 (en) Antibodies
GB0911770D0 (en) Antibody
TWM347415U (en) Band recognition structure
GB0817621D0 (en) Antibody
GB0817622D0 (en) Antibody
GB0812720D0 (en) Gem card
GB0823562D0 (en) Antibodies
GB0806230D0 (en) Antibodies

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed